Trial · NCT02516553
BI 894999 First in Human Dose Finding Study in Advanced Malignancies
NCT02516553, Phase 1, Completed, Boehringer Ingelheim; results first posted 2024-04-15
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. BI 894999 First in Human Dose Finding Study in Advanced Malignancies. Trials, record NCT02516553. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02516553
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- BI 894999 First in Human Dose Finding Study in Advanced Malignancies
- NCT number
- NCT02516553
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 174 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Neoplasms, NUT Carcinoma
- Interventions
- BI 894999
- First posted
- 2015-08-06
- Last updated
- 2024-04-15
- Other registries' IDs
- eudract:2015-001111-12
- Results first posted
- 2024-04-15
- Limitations and caveats
- This trial was closed in accordance with protocol-defined criteria for stopping the trial following assessments of futility. Trial was completed as described in protocol.
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase Ia: Number of Patients With DLTs Observed in the First Cycle | First treatment cycle (the first 21 days for Schedules A and B, the first 28 days for Schedule C). | Number of patients with Dose Limiting Toxicities (DLTs) observed in the first treatment cycle of Phase Ia is reported. The following drug related adverse events (AEs) qualified as DLT: * any Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 non haematological toxicity considered related to trial medication with the following exceptions: * inadequately treated nausea, vomiting or diarrhoea. For fatigue, if present at baseline, there had to be an increase of ≥2 grades * electrolytes abnormalities that were corrected within 72 hours with treatment * any haematologic AE related to the trial medication defined as follows: * CTCAE grade ≥4 neutropenia lasting ≥ 7 days and/or complicated by infection, or * CTCAE grade ≥4 thrombocytopenia, or * CTCAE grade≥ 3 thrombocytopenia coupled with grade ≥ 2 of bleeding, or * febrile neutropenia CTCAE grade 3 or higher. * any other drug-related AE preventing the patient from taking his treatment according to the given schedule. |
| Primary | Phase Ib: Number of Patients With DLTs Observed During the On-treatment Period | Date of the first administration of study treatment until date of the last administration of study treatment + 30 days residual effect period, up to 883 days. | Number of patients with Dose Limiting Toxicities (DLTs) observed during the on-treatment period of Phase Ib is reported. The following drug related adverse events (AEs) qualified as DLT: * any Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 non haematological toxicity considered related to trial medication with the following exceptions: * inadequately treated nausea, vomiting or diarrhoea. For fatigue, if present at baseline, there had to be an increase of ≥2 grades * electrolytes abnormalities that were corrected within 72 hours with treatment * any haematologic AE related to the trial medication defined as follows: * CTCAE grade ≥4 neutropenia lasting ≥ 7 days and/or complicated by infection, or * CTCAE grade ≥4 thrombocytopenia, or * CTCAE grade≥ 3 thrombocytopenia coupled with grade ≥ 2 of bleeding, or * febrile neutropenia CTCAE grade 3 or higher. * any other drug-related AE preventing the patient from taking his treatment according to the given schedule. |
| Secondary | Phase Ia: Number of Patients With DLTs Observed During the On-treatment Period | Date of the first administration of study treatment until date of the last administration of study treatment + 30 days residual effect period, up to 463 days. | Number of patients with DLTs observed during the on-treatment period of Phase Ia is reported. The following drug related adverse events (AEs) qualified as DLT: * any Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 non haematological toxicity considered related to trial medication with the following exceptions: * inadequately treated nausea, vomiting or diarrhoea. For fatigue, if present at baseline, there had to be an increase of ≥2 grades * electrolytes abnormalities that were corrected within 72 hours with treatment * any haematologic AE related to the trial medication defined as follows: * CTCAE grade ≥4 neutropenia lasting ≥ 7 days and/or complicated by infection, or * CTCAE grade ≥4 thrombocytopenia, or * CTCAE grade≥ 3 thrombocytopenia coupled with grade ≥ 2 of bleeding, or * febrile neutropenia CTCAE grade 3 or higher. * any other drug-related AE preventing the patient from taking his treatment according to the given schedule. |
| Secondary | Phase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24) | 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h and 23h55min after administration of first BI 894999 dose on Day 1 of Cycle 1. | Area under the concentration-time curve of BI 894999 in plasma over the time interval from 0 to 24 hours after administration of the first dose (AUC0-24) for Phase Ia and Phase Ib is reported. |
| Secondary | Phase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma After the First Dose (Cmax) | 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h and 23h55min after administration of first BI 894999 dose on Day 1 of Cycle 1. | Maximum measured concentration of BI 894999 in plasma after the first dose (Cmax) for Phase 1a and Phase 1b is reported. |
| Secondary | Phase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ, ss) | 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, and at 23h55min (Schedule A) or 24h (Schedule B & C) following administration on day 14 (Schedule A & B) or day 21 (Schedule C). | Area under the concentration-time curve of BI 894999 in plasma at steady state over a uniform dosing interval τ (AUCτ, ss) for Phase Ia and Ib is reported. The dosing interval is 24 hours (h) for all dose groups. |
| Secondary | Phase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax, ss) | 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, and at 23h55min (Schedule A) or 24h (Schedule B & C) following administration on day 14 (Schedule A & B) or day 21 (Schedule C). | Maximum measured concentration of BI 894999 in plasma at steady state over a uniform dosing interval τ (Cmax, ss) for Phase Ia and Phase Ib is reported. The dosing interval is 24 hours (h) for all dose groups. |
| Secondary | Phase Ia and Phase Ib: Objective Response (OR) | Up to 15 months for Phase 1a and up to 28 months for Phase Ib. | OR was defined as best overall response (BOR) of complete response (CR) or partial response (PR) with tumour assessment during treatment period for each schedule. For DLBCL patients, a minor response according to Response Evaluation Criteria In Lymphoma 2017 (RECIL 2017) was not part of an objective response. BOR was determined from first treatment administration until the earliest of disease progression, death or last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent, according to the following criteria depending on the type of cancer: * solid tumour patients and mCRPC patients with measurable disease: CT and/ or MRI according to RECIST v1.1, every 2 cycles; * mCRPC patients without measurable disease: bone scan and PSA level according to Prostate Cancer Clinical Trials Working Group 3, every 4 cycles; * DLBCL patients:FDG-PET/CT scans according to RECIL 2017; every 2 cycles. |
| Secondary | Phase Ib: Progression-free Survival or (PFS) or Radiological PFS for mCRPC Patients With Non-measurable Disease by RECIST v1.1 | Up to 28 months. | Progression-free survival (PFS) was defined as the time from date of start of BI 894999 to the date of objective disease progression ((PD) defined as 20% increase in the sum of the longest diameter of target lesions) or death, whichever is earlier for SCLC patients, CRC patients, mCRPC patients with measurable disease by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) and NC patients, with tumour assessment every 2 cycles according to RECIST v1.1 during treatment period or Radiological PFS with tumour assessment by bone scan every 4 cycles for mCRPC patients with non-measurable disease by RECIST v1.1. For patients with 'event' as an outcome for PFS: \- PFS \[days\] = date of outcome - date of first treatment administration + 1. For patients with 'censored' as an outcome for PFS: \- PFS (censored) \[days\] = date of outcome - date of first treatment administration + 1. The Kaplan-Meier method was used to calculate the estimates. |
| Secondary | Phase Ib: Best Overall Response | Imaging and assessment performed every 2 cycles (solid tumours patients) or 4 cycles (mCRPC patients) for the entire treatment period, up to 28 months. | Best overall response (BOR) was determined from first treatment administration until the earliest of disease progression, death or last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent, according to the following criteria depending on the type of cancer: * solid tumour patients and mCRPC patients with measurable disease: Computerized tomography (CT) and/ or magnetic resonance imaging (MRI) according to RECIST v1.1, every 2 cycles; * mCRPC patients without measurable disease: bone scan and PSA level according to Prostate Cancer Clinical Trials Working Group 3, every 4 cycles. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Phase Ia: Number of Patients With DLTs Observed in the First Cycle | First treatment cycle (the first 21 days for Schedules A and B, the first 28 days for Schedule C). | Maximum Tolerated Dose (MTD) Evaluation Set (MTDS): Included all patients in the treated set (TS) of Phase 1a who were not replaced for the MTD determination. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Phase Ib: Number of Patients With DLTs Observed During the On-treatment Period | Date of the first administration of study treatment until date of the last administration of study treatment + 30 days residual effect period, up to 883 days. | For Phase Ib - Schedule B SCLC, Phase Ib - Schedule B mCRPC, DMC decided on 28Nov2018 to lower the dose of SCLC and mCRPC due to safety concern, thus patients treated prior the decision received 2.5mg BI 894999 and patients treated after the decision received 2mg. For Phase Ib - Schedule C NC, the dose was lowered since DMC reclaimed the MTD as 6/3mg on 08Jul2020 after 1 patient already treated with 7/3.5mg, so the first patient in NC and all the following patients were treated with 6/3mg. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Phase Ia: Number of Patients With DLTs Observed During the On-treatment Period | Date of the first administration of study treatment until date of the last administration of study treatment + 30 days residual effect period, up to 463 days. | Included all patients in Phase 1a who were dispensed study treatment and were documented to have taken at least one dose of the study treatment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Phase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24) | 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h and 23h55min after administration of first BI 894999 dose on Day 1 of Cycle 1. | Pharmacokinetic (PK) analysis Set (PKS): Included all patients in the treated set (TS) who have at least one evaluable PK parameters.~In phase Ib, solid tumor patients (SCLC, mCRPC, CRC and NC) are combined by dose level (2 or 2.5mg) as data of all solid tumor patients were needed since no differences were expected, but the NC patients alone were differentiated in an additional subgroup as it was the initial indication for BI 894999. | nanomole * hour /Liter (nmol*h/L) | GEOMETRIC_MEAN |
| SECONDARY | Phase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma After the First Dose (Cmax) | 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h and 23h55min after administration of first BI 894999 dose on Day 1 of Cycle 1. | Pharmacokinetic (PK) analysis Set (PKS): Included all patients in the treated set (TS) who have at least one evaluable PK parameters.~In phase Ib, solid tumor patients (SCLC, mCRPC, CRC and NC) are combined by dose level (2 or 2.5mg) as data of all solid tumor patients were needed since no differences were expected, but the NC patients alone were differentiated in an additional subgroup as it was the initial indication for BI894999. | nanomole/L (nmol/L) | GEOMETRIC_MEAN |
| SECONDARY | Phase Ia and Phase Ib: Area Under the Concentration-time Curve of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ, ss) | 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, and at 23h55min (Schedule A) or 24h (Schedule B & C) following administration on day 14 (Schedule A & B) or day 21 (Schedule C). | Pharmacokinetic (PK) analysis Set (PKS): Included all patients in the treated set (TS) who have at least one evaluable PK parameters.~In phase Ib, solid tumor patients (SCLC, mCRPC, CRC and NC) are combined by dose level (2 or 2.5mg) as data of all solid tumor patients were needed since no differences were expected, but the NC patients alone were differentiated in an additional subgroup as it was the initial indication for BI 894999. | nanomole *hour/Liter (nmol*h/)L | GEOMETRIC_MEAN |
| SECONDARY | Phase Ia and Phase Ib: Maximum Measured Concentration of BI 894999 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax, ss) | 5 minutes (min) before and at 30 min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, and at 23h55min (Schedule A) or 24h (Schedule B & C) following administration on day 14 (Schedule A & B) or day 21 (Schedule C). | Pharmacokinetic (PK) analysis Set (PKS): Included all patients in the treated set (TS) who have at least one evaluable PK parameters.~In phase Ib, solid tumor patients (SCLC, mCRPC, CRC and NC) are combined by dose level (2 or 2.5mg) as data of all solid tumor patients were needed since no differences were expected, but the NC patients alone were differentiated in an additional subgroup as it was the initial indication for BI894999. | nanomole/Liter (nmol/L) | GEOMETRIC_MEAN |
| SECONDARY | Phase Ia and Phase Ib: Objective Response (OR) | Up to 15 months for Phase 1a and up to 28 months for Phase Ib. | For Phase Ib - Schedule B SCLC, Phase Ib - Schedule B mCRPC, DMC decided on 28Nov2018 to lower the dose of SCLC and mCRPC due to safety concern, thus patients treated prior the decision received 2.5mg BI 894999 and patients treated after the decision received 2mg. For Phase Ib - Schedule C NC, the dose was lowered since DMC reclaimed the MTD as 6/3mg on 08Jul2020 after 1 patient already treated with 7/3.5mg, so the first patient in NC and all the following patients were treated with 6/3mg. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Phase Ib: Progression-free Survival or (PFS) or Radiological PFS for mCRPC Patients With Non-measurable Disease by RECIST v1.1 | Up to 28 months. | For Phase Ib - Schedule B SCLC, Phase Ib - Schedule B mCRPC, DMC decided on 28Nov2018 to lower the dose of SCLC and mCRPC due to safety concern, thus patients treated prior the decision received 2.5mg BI 894999 and patients treated after the decision received 2mg. For Phase Ib - Schedule C NC, the dose was lowered since DMC reclaimed the MTD as 6/3mg on 08Jul2020 after 1 patient already treated with 7/3.5mg, so the first patient in NC and all the following patients were treated with 6/3mg. | Weeks | MEDIAN |
| SECONDARY | Phase Ib: Best Overall Response | Imaging and assessment performed every 2 cycles (solid tumours patients) or 4 cycles (mCRPC patients) for the entire treatment period, up to 28 months. | For Phase Ib - Schedule B SCLC, Phase Ib - Schedule B mCRPC, DMC decided on 28Nov2018 to lower the dose of SCLC and mCRPC due to safety concern, thus patients treated prior the decision received 2.5mg BI 894999 and patients treated after the decision received 2mg. For Phase Ib - Schedule C NC, the dose was lowered since DMC reclaimed the MTD as 6/3mg on 08Jul2020 after 1 patient already treated with 7/3.5mg, so the first patient in NC and all the following patients were treated with 6/3mg. | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group185
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase Ia: Number of Patients With DLTs Observed in the First Cycle | Phase Ia - Schedule A: 0.2 mg BI 894999 | 0 | Participants | ||
| Phase Ia: Number of Patients With DLTs Observed in the First Cycle | Phase Ia - Schedule A: 0.5 mg BI 894999 | 0 | Participants | ||
| Phase Ia: Number of Patients With DLTs Observed in the First Cycle | Phase Ia - Schedule A: 1 mg BI 894999 | 0 | Participants | ||
| Phase Ia: Number of Patients With DLTs Observed in the First Cycle | Phase Ia - Schedule A: 1.5 mg BI 894999 | 0 | Participants | ||
| Phase Ia: Number of Patients With DLTs Observed in the First Cycle | Phase Ia - Schedule A: 2 mg BI 894999 | 3 | Participants | ||
| Phase Ia: Number of Patients With DLTs Observed in the First Cycle | Phase Ia - Schedule A: 5 mg BI 894999 | 2 | Participants | ||
| Phase Ia: Number of Patients With DLTs Observed in the First Cycle | Phase Ia - Schedule B: 1.5 mg BI 894999 | 1 | Participants | ||
| Phase Ia: Number of Patients With DLTs Observed in the First Cycle | Phase Ia - Schedule B: 2 mg BI 894999 | 0 | Participants | ||
| Phase Ia: Number of Patients With DLTs Observed in the First Cycle | Phase Ia - Schedule B: 2.5 mg BI 894999 | 2 | Participants | ||
| Phase Ia: Number of Patients With DLTs Observed in the First Cycle | Phase Ia - Schedule C: 5/2.5 mg BI 894999 | 0 | Participants |
1 to 10 of 185Source ClinicalTrials.gov
See all 185 results by groupParticipant flow66
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phase Ia - Schedule A: 0.2 mg BI 894999 | 2 | |
| Overall Study | STARTED | Phase Ia - Schedule A: 0.5 mg BI 894999 | 2 | |
| Overall Study | STARTED | Phase Ia - Schedule A: 1 mg BI 894999 | 3 | |
| Overall Study | STARTED | Phase Ia - Schedule A: 1.5 mg BI 894999 | 6 | |
| Overall Study | STARTED | Phase Ia - Schedule A: 2 mg BI 894999 | 6 | |
| Overall Study | STARTED | Phase Ia - Schedule A: 5 mg BI 894999 | 2 | |
| Overall Study | STARTED | Phase Ia - Schedule B: 1.5 mg BI 894999 | 6 | |
| Overall Study | STARTED | Phase Ia - Schedule B: 2 mg BI 894999 | 6 | |
| Overall Study | STARTED | Phase Ia - Schedule B: 2.5 mg BI 894999 | 13 | |
| Overall Study | STARTED | Phase Ia - Schedule C: 5/2.5 mg BI 894999 | 4 |
1 to 10 of 66Source ClinicalTrials.gov
See all 66 participant flowAdverse events9,650
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Phase Ia - Schedule A: 0.2 mg BI 894999 | 0 | 2 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase Ia - Schedule A: 0.5 mg BI 894999 | 1 | 2 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase Ia - Schedule A: 1 mg BI 894999 | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase Ia - Schedule A: 1.5 mg BI 894999 | 1 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase Ia - Schedule A: 2 mg BI 894999 | 1 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase Ia - Schedule A: 5 mg BI 894999 | 0 | 2 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase Ia - Schedule B: 1.5 mg BI 894999 | 2 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase Ia - Schedule B: 2 mg BI 894999 | 2 | 6 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase Ia - Schedule B: 2.5 mg BI 894999 | 4 | 13 | |
| other | Anaemia | Blood and lymphatic system disorders | Phase Ia - Schedule C: 5/2.5 mg BI 894999 | 0 | 4 |
1 to 10 of 9,650Source ClinicalTrials.gov
See all 9,650 adverse eventsAdverse event totals75
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Phase Ia - Schedule A: 0.2 mg BI 894999 | 0 | 2 |
| Total, all-cause mortality | Phase Ia - Schedule A: 0.5 mg BI 894999 | 0 | 2 |
| Total, all-cause mortality | Phase Ia - Schedule A: 1 mg BI 894999 | 0 | 3 |
| Total, all-cause mortality | Phase Ia - Schedule A: 1.5 mg BI 894999 | 1 | 6 |
| Total, all-cause mortality | Phase Ia - Schedule A: 2 mg BI 894999 | 1 | 6 |
| Total, all-cause mortality | Phase Ia - Schedule A: 5 mg BI 894999 | 0 | 2 |
| Total, all-cause mortality | Phase Ia - Schedule B: 1.5 mg BI 894999 | 1 | 6 |
| Total, all-cause mortality | Phase Ia - Schedule B: 2 mg BI 894999 | 1 | 6 |
| Total, all-cause mortality | Phase Ia - Schedule B: 2.5 mg BI 894999 | 2 | 13 |
| Total, all-cause mortality | Phase Ia - Schedule C: 5/2.5 mg BI 894999 | 0 | 4 |
1 to 10 of 75Source ClinicalTrials.gov
See all 75 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37556913 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02516553
GET https://conductscience.org/api/trials/v1/NCT02516553/results?page=2